Status:
COMPLETED
Aripiprazole for Schizophrenia Outpatients Completing BMS Clinical Trials
Lead Sponsor:
Otsuka Pharmaceutical Development & Commercialization, Inc.
Collaborating Sponsors:
Otsuka America Pharmaceutical
Conditions:
Schizophrenia
Eligibility:
All Genders
18-70 years
Phase:
PHASE3
Brief Summary
The purpose of this study is to provide aripiprazole to schizophrenic outpatients and Community Treated Patients who are currently receiving aripiprazole therapy on another BMS sponsored clinical tria...
Eligibility Criteria
Inclusion
- Currently receiving aripiprazole at time of screening
- Men and women ages 18 to 70
Exclusion
- All patients previously discontinued from an aripiprazole study for any reason
- Active alcohol or substance abuse
- Patients who represent a significant risk of committing suicide
- Patients with clinically significant abnormal laboratory test results, vital signs or ECG findings
Key Trial Info
Start Date :
March 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2012
Estimated Enrollment :
119 Patients enrolled
Trial Details
Trial ID
NCT00239356
Start Date
March 1 2003
End Date
October 1 2012
Last Update
December 19 2014
Active Locations (20)
Enter a location and click search to find clinical trials sorted by distance.
1
Local Institution
Ottawa, Ontario, Canada
2
Local Institution
Sherbrooke, Quebec, Canada
3
Local Institution
Rijeka, Croatia
4
Local Institution
Zagreb, Croatia